TruBridge Framtida tillväxt
Future kriterier kontrolleras 3/6
TruBridge förväntas öka vinsten och intäkterna med 62.4% och 3.8% per år respektive medan EPS förväntas växa med 62.4% per år.
Viktig information
62.4%
Tillväxttakt i vinsten
62.37%
Tillväxttakt för EPS
| Healthcare Services vinsttillväxt | 22.1% |
| Intäkternas tillväxttakt | 3.8% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 12 Jun 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jun 26
TBRG: Pending IKS Buyout Will Likely Expose Execution Risks
The analyst price target for TruBridge has moved from $15 to $23. Analysts attribute this change to adjustments in fair value assumptions, a lower discount rate, and updated expectations for revenue growth, profit margins, and future P/E.
Uppdatering av berättelse • Apr 17
TBRG: Potential IKS Deal And EHR Execution Will Shape Future Re Rating
TruBridge's analyst fair value estimate has shifted from $21.00 to $22.00 as analysts update their models around potential IKS-related opportunities, as well as recent mixed price target moves across the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to the potential IKS transaction as aligned with TruBridge's ongoing review of its business.
Ny berättelse • Apr 16
AI And Global Delivery Expansion Will Reshape Rural Hospital Solutions Over The Next Decade
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and patient care software and services to hospitals, with a focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 14
TruBridge: Potential Takeover Target, Upside Fundamentally Supported
Summary TruBridge, Inc. is undergoing an operational turnaround with margin expansion, rising EBITDA, and a shift to high-quality recurring revenue. A potential $600 million takeover by Inventurus Knowledge Systems offers a 36–40% premium to current prices but introduces binary deal risk. TBRG’s recurring revenue remains high at 94%, with stable cash flows and improved profitability despite flat top-line growth. The implied takeover valuation aligns with sector multiples, suggesting the upside is fundamentally supported, not purely speculative. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 02
TBRG: Revenue Cycle Momentum And EHR Stability Will Support Future Re Rating
Analysts have trimmed their price targets on TruBridge, with the average moving from about $22.67 to $21.00 as they weigh a slightly higher discount rate, modestly different revenue growth and margin assumptions, and a lower future P/E multiple against the company's mix of Revenue Cycle Management growth potential and stable Electronic Health Records operations. Analyst Commentary Recent research updates on TruBridge reflect a mix of optimism around the business model and caution around execution and valuation.Ny berättelse • Apr 02
AI Expansion And Global Delivery Shift Will Shape A Steady But Capped Future
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and electronic health record solutions to hospitals and healthcare providers, with a particular focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Analysartikel • Feb 12
Returns At TruBridge (NASDAQ:TBRG) Appear To Be Weighed Down
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Uppdatering av berättelse • Jan 28
TBRG: Revenue Cycle Focus And EHR Stability Will Test Execution Outcomes
Narrative Update The analyst price target for TruBridge has shifted modestly higher to about $22.67 per share, supported by analysts citing the potential of its Revenue Cycle Management focus alongside a steadier Electronic Health Records business, while still calling out execution risk after recent periods of low growth. Analyst Commentary Recent research points to a mixed but constructive view on TruBridge, with analysts focusing on the shift toward Revenue Cycle Management and the steadier Electronic Health Records business when considering valuation and execution risk.Uppdatering av berättelse • Jan 12
TBRG: Revenue Cycle Realignment And EHR Stability Will Require Steady Execution
Narrative Update The analyst price target for TruBridge now centers around US$23, a modest lift from the prior US$22.60. Analysts point to the potential of the Revenue Cycle Management opportunity alongside a steadier Electronic Health Records business, while still flagging execution risk after recent periods of low growth.Uppdatering av berättelse • Dec 17
TBRG: Revenue Cycle Shift Will Demand Proven Execution Before Rerating
Analysts raised their price target on TruBridge modestly, citing improving growth prospects from the company’s shift toward revenue cycle management as evidence builds of its long-term earnings potential. Analyst Commentary Bullish Takeaways Bullish analysts view the company’s realignment toward revenue cycle management as a structurally higher growth opportunity compared with its legacy clinical software offerings.Uppdatering av berättelse • Dec 03
TBRG: Revenue Cycle Pivot Will Require Clear Execution Evidence In 2025
Analysts have nudged their price target on TruBridge slightly higher to approximately $22.60 per share. This reflects increased confidence that the company’s shift toward revenue cycle management can unlock more attractive, evidence-based growth than its legacy clinical software focus.Uppdatering av berättelse • Nov 19
TBRG: Measured Optimism Will Depend On Evidence Of Execution In 2025
TruBridge's analyst price target has been revised downward from $24.75 to $22.60. Analysts cite recent coverage reflecting cautious optimism about the company's strategic shift toward revenue cycle management, while awaiting clearer evidence of execution before turning more positive.Analysartikel • Nov 14
Solid Earnings Reflect TruBridge's (NASDAQ:TBRG) Strength As A Business
Even though TruBridge, Inc.'s ( NASDAQ:TBRG ) recent earnings release was robust, the market didn't seem to notice. We...Uppdatering av berättelse • Aug 15
AI And India Hub Will Boost Future Healthcare Efficiency
Despite a notable improvement in TruBridge’s net profit margin and a significant decline in its future P/E ratio, the consensus analyst price target has been sharply revised down from $29.25 to $24.75. What's in the News TruBridge lowered its full-year 2025 revenue guidance to $345 million-$350 million from a previous range of $345 million-$360 million; third quarter 2025 revenue is forecasted at $85 million-$87 million.Ny berättelse • May 31
Digital Automation And AI Will Drive Healthcare Transformation
Increased AI-driven automation, expanded SaaS offerings, and digital transformation are expected to boost operational efficiency, recurring revenue growth, and earnings quality.Analysartikel • Feb 14
Would TruBridge (NASDAQ:TBRG) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jan 17
TruBridge, Inc. (NASDAQ:TBRG) Shares Fly 27% But Investors Aren't Buying For Growth
TruBridge, Inc. ( NASDAQ:TBRG ) shares have continued their recent momentum with a 27% gain in the last month alone...Analysartikel • Nov 13
TruBridge, Inc.'s (NASDAQ:TBRG) Business And Shares Still Trailing The Industry
TruBridge, Inc.'s ( NASDAQ:TBRG ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2027 | 370 | 26 | 36 | 63 | 3 |
| 12/31/2026 | 355 | 26 | 30 | 57 | 4 |
| 3/31/2026 | 346 | 4 | 30 | 47 | N/A |
| 12/31/2025 | 347 | 4 | 20 | 37 | N/A |
| 9/30/2025 | 347 | 3 | 21 | 37 | N/A |
| 6/30/2025 | 345 | -11 | 16 | 34 | N/A |
| 3/31/2025 | 345 | -18 | 22 | 39 | N/A |
| 12/31/2024 | 342 | -20 | 13 | 31 | N/A |
| 9/30/2024 | 337 | -59 | -10 | 10 | N/A |
| 6/30/2024 | 335 | -54 | -18 | 3 | N/A |
| 3/31/2024 | 334 | -52 | -33 | -10 | N/A |
| 12/31/2023 | 337 | -47 | -22 | -1 | N/A |
| 9/30/2023 | 337 | -1 | -7 | 15 | N/A |
| 6/30/2023 | 337 | 5 | 1 | 23 | N/A |
| 3/31/2023 | 335 | 11 | 9 | 30 | N/A |
| 12/31/2022 | 327 | 16 | 13 | 32 | N/A |
| 9/30/2022 | 317 | 18 | 26 | 43 | N/A |
| 6/30/2022 | 305 | 19 | 19 | 34 | N/A |
| 3/31/2022 | 290 | 22 | 33 | 46 | N/A |
| 12/31/2021 | 281 | 18 | 37 | 48 | N/A |
| 9/30/2021 | 273 | 16 | 42 | 51 | N/A |
| 6/30/2021 | 272 | 18 | 51 | 57 | N/A |
| 3/31/2021 | 263 | 14 | 50 | 55 | N/A |
| 12/31/2020 | 264 | 14 | 42 | 49 | N/A |
| 9/30/2020 | 268 | 22 | 45 | 51 | N/A |
| 6/30/2020 | 269 | 20 | 46 | 51 | N/A |
| 3/31/2020 | 275 | 20 | 39 | 43 | N/A |
| 12/31/2019 | 275 | 20 | N/A | 44 | N/A |
| 9/30/2019 | 276 | 16 | N/A | 35 | N/A |
| 6/30/2019 | 277 | 18 | N/A | 34 | N/A |
| 3/31/2019 | 279 | 17 | N/A | 29 | N/A |
| 12/31/2018 | 280 | 17 | N/A | 24 | N/A |
| 9/30/2018 | 286 | -11 | N/A | 20 | N/A |
| 6/30/2018 | 284 | -15 | N/A | 16 | N/A |
| 3/31/2018 | 284 | -13 | N/A | 17 | N/A |
| 12/31/2017 | 277 | -17 | N/A | 24 | N/A |
| 9/30/2017 | 263 | 6 | N/A | 23 | N/A |
| 6/30/2017 | 261 | 5 | N/A | 26 | N/A |
| 3/31/2017 | 262 | 6 | N/A | 11 | N/A |
| 12/31/2016 | 267 | 4 | N/A | 2 | N/A |
| 9/30/2016 | 247 | 5 | N/A | 2 | N/A |
| 6/30/2016 | 227 | 7 | N/A | 5 | N/A |
| 3/31/2016 | 206 | 11 | N/A | 18 | N/A |
| 12/31/2015 | 182 | 18 | N/A | 31 | N/A |
| 9/30/2015 | 184 | 21 | N/A | 39 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: TBRG s prognostiserade vinsttillväxt ( 62.4% per år) är över sparkvoten ( 3.5% ).
Resultat vs marknad: TBRG s intäkter ( 62.4% per år) förväntas växa snabbare än marknaden för US ( 18.2% per år).
Höga tillväxtresultat: TBRG s intäkter förväntas växa avsevärt under de kommande 3 åren.
Intäkt vs marknad: TBRG s intäkter ( 3.8% per år) förväntas växa långsammare än marknaden för US ( 12.9% per år).
Hög tillväxtintäkter: TBRG s intäkter ( 3.8% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om TBRG s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 12:16 |
| Aktiekurs vid dagens slut | 2026/07/08 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
TruBridge, Inc. bevakas av 22 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Stephanie Davis | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |